ANADYS HALTS STUDIES FOR ORAL HEPATITIS C DRUG

A A

Anadys Pharmaceuticals has suspended dosing hepatitis C virus (HCV) patients in its ongoing Phase Ib clinical trial with ANA975 pending additional analysis of recently obtained information from pre-clinical 13-week toxicology studies in animals.

Preliminary analysis of this information revealed various new observations which appear consistent with intense immune stimulation in animals. Anadys and its collaborator Novartis are in the process of evaluating these observations to determine future course of action.